Clinical Trials Directory

Trials / Unknown

UnknownNCT03985709

Probiotic for Osteoarthritis

Deciphering the Role of the Microbiota in Osteoarthritis for Improving Therapy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Fondazione Don Carlo Gnocchi Onlus · Academic / Other
Sex
All
Age
50 Years – 90 Years
Healthy volunteers
Accepted

Summary

The gut microbiome appears to be a significant contributor to musculoskeletal health and disease. Microbiome composition and its functional implications have been associated with prevention of bone loss and/or reducing fracture risk. Genetic background, gender, dietary intake, and social factors are also important factors which contribute to the musculoskeletal health, as well as to the normal balance of intestinal microbiota. The link between gut microbiota and joint inflammation in murine models of arthritis has been established, and it is now receiving increasing attention in human studies. Recent papers have demonstrated substantial alterations in the gut microbiota in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). These alterations resemble those established in systemic inflammatory conditions (inflammatory bowel disease, spondyloarthritides, psoriasis), which include decreased microbial diversity and lower abundances of bacteria belonging to the Firmicutes phylum that are known to have immunoregulatory properties.These new findings open important future horizons both for understanding disease pathophysiology and for developing novel biomarkers and treatment strategies. Further investigation into the mechanisms linking changes in the microbiome to alterations in bones and joints is necessary. Next Generation Sequencing, metatranscriptomic analysis, and metabolomic approaches may provide yet-greater insight and help further understand these mechanisms. To investigate gut microbiota change will be associated with the sintoms of knee and / or hip OA in italian patients.

Conditions

Interventions

TypeNameDescription
OTHERProbiotic productProbiotic (Lactobacillus casei) once daily taken by 3 months.

Timeline

Start date
2020-02-01
Primary completion
2021-12-31
Completion
2022-07-01
First posted
2019-06-14
Last updated
2019-06-14

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT03985709. Inclusion in this directory is not an endorsement.